Genmab A/S is a Denmark-based biotechnology company. It is engaged in the development of differentiated human antibody therapeutics for the treatment of cancer, as well as other medical conditions, such as relapsing remitting multiple sclerosis. Its product pipeline includes a number of research and development projects in various phases, including Ofatumumab for the treatment of, among others, Waldenstromâ€™s Macroglobulinemia and chronic lymphocytic leukemia; Daratumumab, for the treatment of multiple myeloma; Teprotumumab, aimed at active thyroid eye disease, and HuMax-TF-ADC for the treatment of solid cancers, among others. Additionally, the Company has more than ten product candidates in pre-clinical phase. It develops its projects under worldwide co-development and commercialization agreements with GlaxoSmithKline, H. Lundbeck A/S, Roche, and Seattle Genetics, among others. It has three wholly owned subsidiaries in the Netherlands and the United States.